UTERINE FIBROIDS TREATMENT DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In October 2023, Sumitomo Pharma Canada, Inc., an innovative and entrepreneurial health care company, and Pfizer Canada, a pharmaceutical company announced that Health Canada has issued a Notice of Compliance (NOC) for MYFEMBREE (Relugolix, estradiol, and norethindrone acetate tablets) for the treatment of moderate to severe endometriosis pain in premenopausal women on October 17, 2023. On September 22, 2023, Health Canada authorized MYFEMBREE as a therapy for heavy menstrual bleeding caused by uterine fibroids in premenopausal women. This combination therapy oral drug, which is used once daily, provides women with a new option for treating endometriosis and uterine fibroids symptoms.
• In June 2022, ObsEva SA, a biopharmaceutical company, announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Yselty (linzagolix), an oral GnRH antagonist, for the treatment of moderate to severe uterine fibroids (UF) in adult women of reproductive age (over 18 years old).
• In May 2021, Myovant Sciences, a biopharmaceutical company, and Pfizer Inc., a pharmaceutical and biotechnology corporation, announced that the U.S. Food and Drug Administration (FDA) approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), the first once-daily treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months.
• In May 2020, AbbVie, a pharmaceutical firm, and Neurocrine Biosciences, Inc, a biopharmaceutical business, announced that the U.S. FDA approved ORIAHNN (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) for a treatment period of up to 24 months. ORIAHNN is the first non-surgical, oral medicine licensed by the U.S. FDA for managing heavy monthly bleeding caused by uterine fibroids in premenopausal women.